OGeS’ ability to discover novel targets and biomarkers is based on its unique Oxford Genome Anatomy Project (OGAP^®), one of the world’s largest human protein databases. It offers a data integration framework to explain the size and diversity of the human proteome at the tissue, disease and protein isoform level in a context where it can be exploited for biomedical research.

The OGAP^® database is built on proprietary disease protein information generated in house coupled to genetic and clinical data from 50 different human tissues, including 5,000 cancer membrane proteins. Together they give access to important information covering 58 disease states to support the identification of new disease mechanisms and novel drug targets for drug development, as well as associated surrogate biomarkers

The OGAP^® system integrates all clinical and experimental expression data from:
:: ~1 million human protein peptide sequences
:: ~15,000 “confirmed” genes
:: ~ 50 tissues/organs
:: ~ 58 diseases
:: ~ 8 million SNPs and haplotypes
:: Built in comparative gene mapping from relevant preclinical models

OGAP^® offers a number of advantages to support the discovery of new therapeutic and diagnostic targets for OGeS and its partners:
:: Accelerates the discovery and validation of drug targets
:: Allows re-profiling of previously discovered targets by selecting the best indication to pursue for further development
:: Identifies biomarkers for drug development which can be used for patient selection and efficacy monitoring
:: Allows development of companion diagnostics which can play an important role in delivering improved patient outcomes as well as assisting in the development of targeted therapies

OGAP^® data provide a unique source of highly qualified targets and biomarkers for drug development & diagnostics development which allow the rapid progress from target/biomarker discovery to clinical implementation. OGAP^® is also able to allow the re-profiling of previously discovered targets by selecting the best indication within a given therapeutic area to pursue in terms of development. In order for target/biomarker strategies to impact drug development, their discovery and implementation has to be very rapid, ideally less than 18 months, and therefore to achieve this timeline investigators clearly need access to the support of the OGAP^® data which allows an in silico validation of the target/biomarker with human in vivo data.

:: Harmonised with all public domain “omics” data
:: All data are based on in vivo measurement of proteins rather than in silico predictions, extracted from:
            o Human tissues
            o Patient samples
            o Defined clinical measures
:: Immediate assessment of protein isoforms, spliced genes and SNP variant complexities which all have important disease relevance.
:: Detailed information on protein candidates for the design of analytical reagents and assays.

:: Management of all patient information related to the molecular readout
:: Collate data for each patient, drug treatment and clinical outcome to unique protein biomarkers
:: Fast track to custom tailored biomarker assay on FDA approved diagnostic platform
:: A meaningful link from pre-clinical discovery to clinical development and most importantly disease outcomes.